An interventional study of Quantitative Sensory Testing and questionnaires in Neuropathic Pain and Nociplastic Pain, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.
Among the 132 studies in Neuralgia with a site in France, this one is the 79th largest by planned enrollment of the 102 interventional ones that give a count, is one of 11 that started in 2026, is one of 46 with no phase, reaches primary completion later than 26 of the 39 other live ones, and was the 129th registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:
Hospital Ambroise Paré Paris · Sites in France
Ages 18–80
Hopitaux de Saint-Maurice · Sites in France
Ages 5–18
Poitiers University Hospital · Sites in France
Ages 18–80
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18–85
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 34 · Phase 3 15 · Phase 4 7
First in 2001; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 62 across the 102 interventional studies, 81 across the 30 observational. Of the 82 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 132 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 6 studies filed under Neuralgia — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuralgia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06023706Phase 3Nantes University HospitalStudy Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. | 2027-05-08 |
| NCT04867187Centre Hospitalier Universitaire de Saint EtiennerTMS Efficacy Coupled With Mirror Therapy | 2026-12 |
| NCT06964243Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain | 2026-12-19 |
| NCT06250491Nadine ATTALDeep rTMS (H-coil) for Neuropathic Pain or Fibromyalgia | 2027-01-30 |
| NCT06796595UBOSGAPerioperative Medical Program to Optimize Nerve Regeneration After Robot-assisted Laparoscopic Neurolyses of Pudendal and/or Inferior Cluneal Nerves for Chronic Neuralgias: Results After 1-year Follow-up | 2027-01-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 132 studies in Neuralgia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.
Category 2 Study (Interventional Research with Minimal Risks and Constraints), monocentric, uncontrolled, non-randomized, open-label and prospective.
This study involves conducting tests and questionnaires before and 1 month after the application of a patch administered as part of standard clinical practice.
The criteria were revised on the registry on Nov 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pre-inclusion visit (routine care consultation): Verification of inclusion and exclusion criteria. Inclusion visit (Day 0): Consent signing, questionnaires (ConvergencePP Score/Central Sensitization Inventory, DN4), and a series of tests, followed by the application of the high-concentration capsaicin patch (PCHC) (performed during routine care). Day 30 visit (+7 days): Questionnaires (same as V1 + PGI-c) and a series of tests.
Other: Quantitative Sensory Testing and questionnaires
Quantitative Sensory Testing and questionnaires
Composite criterion
Composite criterion constructed from a Principal Component Analysis including the differences between Day 0 (before patch application) and Day 30 in pain perception thresholds (to cold, heat, pressure, and mechanical stimulation) in both the area treated with the high-concentration capsaicin patch and the corresponding dermatome, as well as the change in the pain receptive field area in the treated zone and the area under the curve of temporal summation measurements.
Time frame: Difference between Day 0 and Day 30
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (1)
Difference in pressure pain thresholds in the treated area
Time frame: Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (2)
Difference in mechanical stimulation pain thresholds
Time frame: Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (3)
Difference in cold pain thresholds in the treated area
Time frame: Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (4)
Difference in heat pain thresholds in the treated area
Time frame: Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (5)
Difference in pain receptive field area
Time frame: Between before and 30 days after patch application
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (1)
Difference in pressure pain thresholds in an area of the dermatome not directly treated by the patch: * Ipsilateral retro-malleolar groove (S2 root) for inferior cluneal nerve neuralgia treatment, * Posterior iliac crest relief, 7 cm from the midline (L1) for ilio-inguinal or ilio-hypogastric neuralgia treatment, * Perineal body (S4) for sacrococcygeal plexus neuralgia treatment.
Time frame: Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (2)
Difference in mechanical stimulation pain thresholds in an area of the dermatome not directly treated by the patch
Time frame: Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (3)
Difference in cold pain thresholds in an area of the dermatome not directly treated by the patch.
Time frame: Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (4)
Difference in heat pain thresholds in an area of the dermatome not directly treated by the patch.
Time frame: Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (5)
Difference in the area under the curve of temporal summation measurements in the treated area
Time frame: Between before and 1 month after patch application.
Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (6)
Difference in the duration of pain persistence after the end of temporal summation (in seconds).
Time frame: Between before and 1 month after patch application.
Measure the patient's therapeutic response to the treatment
Patient Global Impression of Change (PGI-C). The therapeutic response is defined as a patient who scores 1 to 3 on the PGI-C.
Time frame: Day 30
Evaluate the predictive value of temporal summation with regard to the therapeutic response to the high-concentration capsaicin patch
Investigation of a relevant threshold for temporal summation to predict the therapeutic response. Quantification of the positive predictive value.
Time frame: Between before and 1 month after patch application.
Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data
Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data. The Convergences PP score is a clinical questionnaire used to diagnose sensitization in the pelvic region. A score is considered positive from 5/10 (sensitivity = 95%, specificity = 87%). The Central Sensitization Inventory (CSI) is a self-administered questionnaire used to diagnose central sensitization. A score is considered positive from 40/100. Correlations between the Convergences PP score, CSI, and semi-objective sensitization data (pain thresholds and temporal summation) will be measured using Spearman's correlation coefficient to explore the relationships between these variables.
Time frame: Between before and 1 month after patch application
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2028, 15 months later.
Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 15 months is below that.
Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.